Gentle Patches GLP-1 Review: A Patch Named After A Drug It Does Not Contain

1. The physics of the delivery route

Start with the thing that cannot be argued with. Skin is a barrier before it is anything else, and the barrier is the stratum corneum — a dense, lipid-rich, largely dead outer layer whose job is to keep the outside out. Its practical exclusion limit for passive diffusion has been characterised for decades as roughly 500 daltons. That is the 500 Dalton rule, and it is why the successful transdermal patches you can name deliver small molecules: nicotine at 162 daltons, fentanyl at 337, oestradiol at 272, scopolamine at 303.

Semaglutide is a 31-residue peptide with a molecular weight of about 4,114 daltons. Tirzepatide is about 4,813. They are eight to ten times over the ceiling, and they are also peptides, which skin enzymes degrade. This is precisely why semaglutide is injected, and why making an oral version at all required an absorption enhancer and a tablet that must be taken on an empty stomach with a sip of water — an engineering problem that took Novo Nordisk years and a great deal of money to solve for the gut, let alone the skin.

So the sentence “GLP-1 patch” describes something that cannot exist as the name implies. We want to be exact about the accusation, though, because it matters: Gentle Patches never claims its patch contains semaglutide. It claims the opposite by omission — zero mentions across 83 listings. The problem is not a hidden drug. The problem is a name borrowed from a drug class to sell botanicals, in a format that could not have carried the drug even if it were there.

2. The arithmetic on the headline claim

The landing page runs a four-stat bar: 12,000+ happy customers, 10,000+ five-star reviews, 4.9/5 average rating, and then — “94% Users Lost 20+ Pounds After Just 3–4 Weeks of Daily Use.” The first three are ordinary marketing. The fourth is a quantified efficacy claim, and it is worth doing the division.

Twenty pounds in three weeks is 6.7 pounds a week. In four weeks it is 5.0. Take the midpoint of the range the page itself gives and you get about 5.7 pounds a week. Now the comparator: in STEP 1, published in the New England Journal of Medicine in 2021, adults with obesity on semaglutide 2.4 mg lost about 15% of body weight over 68 weeks, from a mean starting weight of 105.3 kg. That is roughly 35 pounds across 68 weeks — about 0.51 pounds a week. The patch's claimed rate is about eleven times faster. Against tirzepatide 15 mg in SURMOUNT-1, which reached 20.9% over 72 weeks, it is about eight and a half times faster.

Then there is the responder rate. The patch claims 94% of users hit the 20-pound mark. In STEP 1, 69.1% of participants reached 10% weight loss — and they took 68 weeks on a weekly injection of the most effective single agent then available. A 94% response rate at eleven times the speed is not an impressive result. It is a result that would have made STEP 1 unnecessary.

Set aside the comparison entirely and the number still fails on its own. Sustained loss of five to seven pounds a week is not a target any clinician sets; standard guidance is one to two pounds a week, and rates far above that raise questions about lean mass and gallstones rather than applause. A claim can be too good in a way that is self-refuting, and this one is.

3. What is actually in it, as far as anyone can tell

Three ingredients are named, in prose, on the landing page: berberine extract, green tea extract (EGCG) and cinnamon extract. The page says they are “formulated with 100% natural ingredients that stimulate the production of GLP-1 hormone.” No quantity is given for any of the three, here or anywhere else.

We should be fair about the size argument, because it does not transfer. Berberine is about 336 daltons and EGCG about 458 — both under the 500-dalton threshold, so unlike semaglutide they are not disqualified by mass. Their problems are different ones. Berberine is a quaternary ammonium cation, permanently charged, and charged species cross the lipid stratum corneum poorly; its oral bioavailability is on the order of 1%, which is the standard complaint about it even in its best-supported oral use. EGCG is highly hydrophilic and a poor skin permeant. Neither has randomised evidence of producing weight loss when applied to skin, at any dose — and no dose is offered here to evaluate.

Berberine taken orally is not nothing. It has real, if modest, signal on glycaemic markers, and it earned its nickname honestly enough to be worth a conversation. But that conversation is about capsules with milligrams printed on them, costing perhaps $15 a month, not about an undisclosed quantity in an adhesive. The company also sells the same patch format as anti-mosquito patches, which tells you the manufacturing competence being sold here is adhesive, not pharmacology.

4. The pricing carousel

The site was running two mutually exclusive permanent sales on the day we looked. A sitewide banner announced “SUMMER CLEARANCE – Buy 3, Get 2 FREE, Buy 2, Get 1 FREE.” The landing page, on the same visit, announced “BLACK NOVEMBER: Get Up to 65% OFF.” We fetched both in August. A discount that is always running is not a discount, it is the price.

The 65% figure also does not match the merchandise. The three bundles on the page are marked Save 15%, Save 48% and Save 59%. Nothing reaches 65%, so the headline discount exceeds the best offer actually available beneath it. The savings percentages are calculated against a stated “Bundle Value” — $134.96 and $254.92 — that is itself inflated by free gift bags of Dopamine and NAD+ patches counted at notional retail.

The clearest read on real pricing comes from the structured product data rather than the sales copy. There, a 12-bag Complete 1-Year Results Package sells for as little as $199.31 — about $16.61 a bag. The single bag on the landing page is $34.99. You are being shown the price that is more than double the company's own annual rate, then walked toward a bundle to escape it.

5. Two funnels for one product, and the discounts do not compute

We were subsequently offered the same product as a separate affiliate listing pointing at a different landing page on the same domain. Same patch, same three botanicals, same 94% claim, same $40.00 commission to us — but a different commercial machine bolted underneath. It is worth documenting, because which link a reader happens to click materially changes what they pay and whether they are enrolled in recurring billing.

The first funnel labels every bundle “One-Time Purchase” and contains no recurring language whatsoever. The second carries “Pause, skip or cancel anytime” on all four tiers, which is subscription framing, and prices a single bag at $60.75 against the first page's $34.99. That is a 74% premium on the identical 30-patch bag, from the same seller, on the same day.

Read the last two numeric columns together. Not one of the four advertised discounts survives contact with the company's own anchor price. The nine-bag tier claims 70% off and delivers 30.6%. The six-bag claims 60% and delivers 13.2%. And the three-bag tier claims to save you 50% while charging $156.21 for something it says is worth $149.95 — you pay $6.26 above the anchor and are told you halved it. A discount cannot be negative. That is not aggressive rounding or a stale price; it is a number that contradicts the number printed beside it.

The subscription framing is emptier still. On all four tiers the “Buy once for…” price is identical to the recurring price — $312.44 and $312.44, $60.75 and $60.75. Subscribing to this funnel buys you no discount at all. It buys you recurrence. The one-bag tier nonetheless advertises a “40% discount on every order,” language that implies an ongoing benefit for enrolling when the page's own figures show none. We noted the opposite pattern on the company's NAD+ page, where subscribing genuinely does cost about half as much as buying once; here the mechanism has been kept and the benefit removed.

This funnel also runs a countdown. A strip reads “BLACK FRIDAY SALE - Up to 70% OFF” above a ticking clock. The markup tells you what the clock is: the countdown element is configured with a duration of 15 minutes and persistence explicitly switched off. Because it does not persist, it restarts at fifteen minutes every time the page is loaded or refreshed, and there is no fixed end date anywhere in the page. The Black Friday sale expiring in a quarter of an hour was still expiring in a quarter of an hour when we reloaded it in August. Behind it, the sitewide banner advertises a summer clearance.

Two smaller things confirm the general standard of care. Two tiers promise “Free Priority shippingg.” And the guarantee on this page is stated in its strongest form — “return it within 30 days for a full refund. No questions asked” — which is the claim most directly contradicted by the returns policy quoted above, where opened product is ineligible, postage is yours, and a $5 restocking fee applies to every return.

We are paid the same $40.00 whichever of the two you use. If you intend to buy this product despite everything on this page, use the one-time-purchase funnel rather than the subscription funnel, because the first charges $34.99 for the bag the second charges $60.75 for, and does not enrol you in anything. That is the most useful sentence we can offer a reader determined to try it.

Do Gentle Patches contain semaglutide or tirzepatide?

No. Across the company's entire 83-product catalogue and its GLP-1 landing page, the words semaglutide and tirzepatide do not appear once. The named ingredients are berberine extract, green tea extract (EGCG) and cinnamon extract. The product is called GLP-1 Patches, but it does not contain a GLP-1 receptor agonist and does not claim to.

Could a skin patch deliver semaglutide even if it wanted to?

No. Semaglutide has a molecular weight of about 4,114 daltons and tirzepatide about 4,813. The outer layer of skin, the stratum corneum, effectively excludes passive diffusion of molecules above roughly 500 daltons — the long-established 500 Dalton rule. A GLP-1 receptor agonist is eight to ten times over that ceiling. No adhesive patch can move one through intact skin in a therapeutic amount. This is a property of the molecule and the skin, not of any particular brand.

What is wrong with the 94% claim?

The landing page states that 94% of users lost 20+ pounds after just 3 to 4 weeks of daily use. That is a rate of 5.0 to 6.7 pounds per week. In STEP 1, the registrational trial of semaglutide 2.4 mg, participants lost about 15% of body weight over 68 weeks — roughly 0.5 pounds per week. The patch's claim implies a rate about 11 times faster than the injectable drug, achieved in 94% of users, from a $34.99 patch sold without a prescription.

Is berberine useless, then?

Not useless, but oversold here and undisclosed. Oral berberine has genuine signal for glycaemic markers, though its oral bioavailability is famously poor — on the order of 1%. The problem with this product is different: no dose is stated for berberine anywhere, on any of the 83 listings or the landing page, so there is no amount to evaluate. If you want berberine, buy it orally from a brand that prints milligrams on the label for a fraction of this price.

Does the site carry the required supplement disclaimer?

Yes, and it deserves credit for it. The landing page footer carries the standard DSHEA text: these statements have not been evaluated by the Food and Drug Administration, and this product is not intended to diagnose, treat, cure, or prevent any disease. The difficulty is that this sentence sits on the same page as a claim that 94% of users lost 20+ pounds in 3 to 4 weeks, which is a specific quantified outcome claim.

Is this a subscription trap?

It depends entirely on which of the company's two GLP-1 landing pages you arrive at, which is itself the problem. On the first, every bundle is explicitly labelled One-Time Purchase and the page contains no rebill, recurring, auto-ship or free-trial language at all. On the second, all four tiers carry pause, skip or cancel anytime — subscription framing — and the single bag costs $60.75 instead of $34.99. Neither page uses a free-trial or negative-option mechanic, so this is not a rebill trap in the classic sense, but do not assume the mechanics carry across their products or even across two pages for the same product. The company's NAD+ page is subscription-default too.

Why do I see two different prices for the same patch?

Because the company runs two landing pages for this product simultaneously. One sells a single 30-patch bag for $34.99 and labels every bundle a one-time purchase. The other sells the same bag for $60.75 — 74% more — and frames all four tiers as subscriptions with pause, skip or cancel anytime. On that second page the advertised discounts do not compute against the company's own anchor prices: the nine-bag tier claims 70% off and actually saves 30.6%, and the three-bag tier claims 50% off while costing $6.26 more than the value it is anchored to. If you buy at all, use the cheaper one-time funnel.

Is the Black Friday countdown real?

No. The countdown element on the second landing page is configured in the page markup with a duration of 15 minutes and persistence turned off, and no fixed end date appears anywhere. Because persistence is off, the timer restarts at 15:00 on every page load or refresh. We observed the Black Friday sale expiring within a quarter of an hour, repeatedly, in August, while a summer clearance banner ran above it.

What does the As Seen In section actually cite?

Nothing identifiable. The section presents three quotation-marked lines about GLP-1 and about the product itself, but names no publication, author or date beside them. One of the quotes is about Gentle Patches specifically — it is getting attention for offering science-backed weight support — with no source attached. Quotation marks are not citations.

What should I do instead if I want a GLP-1 effect?

Get the actual drug. Wegovy is available through NovoCare at $149 a month for the oral tablet and $199 a month for the pen on self-pay, and Zepbound vials run $299 to $499 through LillyDirect depending on dose. Those are real prices for medicines with 68- and 72-week randomised outcome data. A patch at $34.99 is cheaper, but it is not a cheaper version of the same thing — it is a different product wearing the name.